Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:41 am
Author: Getaka|Social: XLinkedIn

SMS Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹301.13Overvalued by 23.38%vs CMP ₹393.00

P/E (42.1) × ROE (11.0%) × BV (₹81.20) × DY (0.10%)

₹147.47Overvalued by 62.48%vs CMP ₹393.00
MoS: -166.5% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹311.7522%Over (-20.7%)
Graham NumberEarnings₹132.0916%Over (-66.4%)
Earnings PowerEarnings₹5.1511%Over (-98.7%)
DCFCash Flow₹83.8713%Over (-78.7%)
Net Asset ValueAssets₹81.217%Over (-79.3%)
EV/EBITDAEnterprise₹151.309%Over (-61.5%)
Earnings YieldEarnings₹95.507%Over (-75.7%)
ROCE CapitalReturns₹159.659%Over (-59.4%)
Revenue MultipleRevenue₹83.665%Over (-78.7%)
Consensus (9 models)₹147.47100%Overvalued
Key Drivers: Wide model spread (₹5–₹312) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 3.5%

*Investments are subject to market risks

Investment Snapshot

64
SMS Pharmaceuticals Ltd scores 64/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health71/100 · Strong
ROCE 12.2% GoodROE 11.0% AverageD/E 0.53 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money65/100 · Strong
FII holding stable No changeDII holding up 0.78% MF buyingPromoter holding at 68.1% Stable
Earnings Quality50/100 · Moderate
OPM stable around 17% Steady
Quarterly Momentum80/100 · Strong
Revenue (4Q): +15% YoY GrowingProfit (4Q): +38% YoY Strong
Industry Rank50/100 · Moderate
P/E 42.1 vs industry 53.8 In-lineROCE 12.2% vs industry 16.4% Average3Y sales CAGR: 15% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:41 am

Market Cap 3,678 Cr.
Current Price 393
Intrinsic Value₹147.47
High / Low 434/175
Stock P/E42.1
Book Value 81.2
Dividend Yield0.10 %
ROCE12.2 %
ROE11.0 %
Face Value 1.00
PEG Ratio11.93

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for SMS Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
SMS Pharmaceuticals Ltd 3,678 Cr. 393 434/17542.1 81.20.10 %12.2 %11.0 % 1.00
Zota Health Care Ltd 3,802 Cr. 1,116 1,740/752 93.50.09 %17.0 %36.0 % 10.0
Suven Life Sciences Ltd 3,888 Cr. 147 303/115 12.40.00 %87.0 %87.2 % 1.00
Aarti Drugs Limited 3,162 Cr. 346 575/31217.0 1470.58 %13.5 %13.0 % 10.0
RPG Life Sciences Ltd 3,105 Cr. 1,878 2,725/1,73129.6 3351.07 %32.8 %25.5 % 8.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of SMS Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 149149135167161246164197173248196242210
Expenses 131126109139133212131165140207157194167
Operating Profit 18232728293333323341394844
OPM % 12%16%20%17%18%14%20%16%19%17%20%20%21%
Other Income 2111121121114
Interest 6666665545666
Depreciation 8888888999101010
Profit before tax 6111315162222202329243431
Tax % 22%24%29%21%26%26%25%28%24%29%24%26%25%
Net Profit 58912121616141721182523
EPS in Rs 0.590.951.101.421.441.881.931.682.032.332.052.682.49

Last Updated: March 3, 2026, 2:40 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 10:15 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 518587611438463465412563520522709783897
Expenses 461500522363369375332442405467592643725
Operating Profit 5786897593908012111555117140172
OPM % 11%15%15%17%20%19%19%22%22%10%16%18%19%
Other Income 21641235355467
Interest 14181716151212111922241923
Depreciation 13171919201922223232323438
Profit before tax 32675642606251916966693118
Tax % 36%48%26%14%33%34%36%33%1%26%25%27%
Net Profit 2035423640413361684496887
EPS in Rs 2.404.154.924.204.784.893.867.208.030.485.837.719.55
Dividend Payout % 8%5%4%5%5%5%6%4%4%62%7%5%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)75.00%20.00%-14.29%11.11%2.50%-19.51%84.85%11.48%-94.12%1125.00%38.78%
Change in YoY Net Profit Growth (%)0.00%-55.00%-34.29%25.40%-8.61%-22.01%104.36%-73.37%-105.59%1219.12%-1086.22%

SMS Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:3%
5 Years:14%
3 Years:15%
TTM:10%
Compounded Profit Growth
10 Years:7%
5 Years:16%
3 Years:0%
TTM:24%
Stock Price CAGR
10 Years:17%
5 Years:22%
3 Years:39%
1 Year:-31%
Return on Equity
10 Years:11%
5 Years:10%
3 Years:7%
Last Year:11%

Last Updated: September 5, 2025, 1:31 pm

Balance Sheet

Last Updated: December 4, 2025, 2:00 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 8888888888899
Reserves 213246286254293331359420485487562664751
Borrowings 167167204149146144157255263254281311324
Other Liabilities 120119158897293103147126165217202221
Total Liabilities 5095406565015195776278308839141,0681,1861,305
Fixed Assets 247277370290279281280457438412437533517
CWIP 39291388184271133303550
Investments 6132137454545454545454548
Other Assets 217221252166187232259321389424556573690
Total Assets 5095406565015195776278308839141,0681,1861,305

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 655961733250409045225082
Cash from Investing Activity + -37-55-79-39-17-35-43-152-27-30-52-123
Cash from Financing Activity + -30-1027-33-15-13-292-12-323147
Net Cash Flow -2-69102-5316-39295
Free Cash Flow 1111-27502315-3-6118-7-2-42
CFO/OP 116%75%93%110%46%70%65%88%52%49%56%73%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-110.00-81.00-115.00-74.00-53.00-54.00-77.00-134.00-148.00-199.00-164.00-171.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 39373618192043683410412295
Inventory Days 9081106114135170191148333243201238
Days Payable 59587982495966709711713095
Cash Conversion Cycle 70616350105131169146270230192238
Working Capital Days 91919-227395748941048588
ROCE %12%21%16%13%18%16%13%17%12%4%11%12%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 64.29%64.32%64.32%64.32%64.67%64.67%64.67%64.67%66.27%66.27%68.07%68.07%
FIIs 0.59%0.67%0.60%0.59%0.17%0.18%0.52%0.31%0.08%0.03%0.28%0.04%
DIIs 0.00%0.00%0.00%0.00%1.98%2.13%2.55%2.55%2.43%3.03%2.88%3.21%
Public 35.12%35.01%35.07%35.10%33.18%33.03%32.27%32.47%31.23%30.68%28.77%28.69%
No. of Shareholders 25,53724,65325,24625,34130,14031,78033,13634,97335,33233,65234,15734,378

Shareholding Pattern Chart

No. of Shareholders

SMS Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 1,859,681 0.26 71.63N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 8.165.89-0.837.357.39
Diluted EPS (Rs.) 8.165.89-0.837.357.39
Cash EPS (Rs.) 11.489.544.2511.829.83
Book Value[Excl.RevalReserv]/Share (Rs.) 72.1563.3654.4055.5648.50
Book Value[Incl.RevalReserv]/Share (Rs.) 72.1563.3654.4055.5648.50
Revenue From Operations / Share (Rs.) 88.2983.7961.6761.4166.53
PBDIT / Share (Rs.) 16.3814.307.0214.1214.71
PBIT / Share (Rs.) 12.5110.583.2210.3212.08
PBT / Share (Rs.) 10.427.810.638.0910.76
Net Profit / Share (Rs.) 7.605.810.458.027.20
NP After MI And SOA / Share (Rs.) 7.805.89-0.837.357.39
PBDIT Margin (%) 18.5517.0711.3722.9922.11
PBIT Margin (%) 14.1612.625.2216.8018.16
PBT Margin (%) 11.799.321.0213.1716.17
Net Profit Margin (%) 8.616.930.7413.0510.82
NP After MI And SOA Margin (%) 8.837.02-1.3511.9611.10
Return on Networth / Equity (%) 10.809.29-1.5313.2315.23
Return on Capital Employeed (%) 13.3812.754.3613.1716.54
Return On Assets (%) 5.994.81-0.807.237.69
Long Term Debt / Equity (X) 0.210.220.260.310.36
Total Debt / Equity (X) 0.480.520.540.550.53
Asset Turnover Ratio (%) 0.710.740.600.610.78
Current Ratio (X) 1.721.621.611.921.59
Quick Ratio (X) 0.840.910.730.640.88
Inventory Turnover Ratio (X) 3.021.861.261.992.35
Dividend Payout Ratio (NP) (%) 4.895.09-35.974.080.00
Dividend Payout Ratio (CP) (%) 3.273.1210.132.690.00
Earning Retention Ratio (%) 95.1194.91135.9795.920.00
Cash Earning Retention Ratio (%) 96.7396.8889.8797.310.00
Interest Coverage Ratio (X) 7.835.162.716.3311.16
Interest Coverage Ratio (Post Tax) (X) 4.643.101.184.606.46
Enterprise Value (Cr.) 2151.851748.52734.331007.491231.25
EV / Net Operating Revenue (X) 2.752.471.411.942.19
EV / EBITDA (X) 14.8214.4412.368.439.88
MarketCap / Net Operating Revenue (X) 2.412.130.931.531.87
Retention Ratios (%) 95.1094.90135.9795.910.00
Price / BV (X) 2.952.811.061.692.57
Price / Net Operating Revenue (X) 2.412.130.931.531.87
EarningsYield 0.030.03-0.010.070.05

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

SMS Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 14/12/1987 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1987PLC008066 and registration number is 008066. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 782.75 Cr. and Equity Capital is Rs. 8.87 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No. 72, H.No. 8-2-334 / 3 & 4, Road No. 5, Opp. SBI Executive Enclave, Hyderabad Telangana 500034Contact not found
Management
NamePosition Held
Mr. Ramesh Babu PotluriChairman & Managing Director
Mr. Vamsi Krishna PotluriExecutive Director
Dr. Sunkara Venkata Satya Shiva PrasadNon Exe.Non Ind.Director
Mr. Trilok PotluriNon Exe.Non Ind.Director
Mr. Sarvepalli SrinivasInd. Non-Executive Director
Mr. Sharvan KudaravalliInd. Non-Executive Director
Dr. Suresh Kumar GangavarapuInd. Non-Executive Director
Mrs. Shanti Sree BolleniInd. Non-Executive Director

FAQ

What is the intrinsic value of SMS Pharmaceuticals Ltd and is it undervalued?

As of 14 April 2026, SMS Pharmaceuticals Ltd's intrinsic value is ₹147.47, which is 62.48% lower than the current market price of ₹393.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (11.0 %), book value (₹81.2), dividend yield (0.10 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of SMS Pharmaceuticals Ltd?

SMS Pharmaceuticals Ltd is trading at ₹393.00 as of 14 April 2026, with a FY2026-2027 high of ₹434 and low of ₹175. The stock is currently near its 52-week high. Market cap stands at ₹3,678 Cr..

How does SMS Pharmaceuticals Ltd's P/E ratio compare to its industry?

SMS Pharmaceuticals Ltd has a P/E ratio of 42.1, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is SMS Pharmaceuticals Ltd financially healthy?

Key indicators for SMS Pharmaceuticals Ltd: ROCE of 12.2 % is moderate. Dividend yield is 0.10 %.

Is SMS Pharmaceuticals Ltd profitable and how is the profit trend?

SMS Pharmaceuticals Ltd reported a net profit of ₹68 Cr in Mar 2025 on revenue of ₹783 Cr. Compared to ₹68 Cr in Mar 2022, the net profit shows a mixed trend.

Does SMS Pharmaceuticals Ltd pay dividends?

SMS Pharmaceuticals Ltd has a dividend yield of 0.10 % at the current price of ₹393.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in SMS Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports